Portfolio Case
  • ·

    MBA from Zhongnan University of Economics and Law and an EMBA from Cheung Kong Graduate School of Business.


    A key member of the investment committee of China Pharmaceutical Innovation and Research Development Association, a member of Bayhelix Group.


    Selected as the ' Most Promising Investor in Shenzhen', 'China Finance Person of The Year 2019', 'China's Best New Venture Capital Manager in 2018'

    ·Efung has beenrated as “Shenzhen Top Ten Venture Capital Institutions“ and “Shenzhen Best Innovative Financial Institution” for many years.
    ·Over 19 years of experience in life science investment. 
    ·Has invested more than 20 domestic and oversea enterprises such as Mindray Medical ,  ChipScreen , Frontier Biotechnologies , Ascentage Pharma , Lifotronic , HaploX, Resverlogix, Centrexion Therapeutics, Apexigen and etc.

Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services